CA3066942A1 - Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders - Google Patents

Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders Download PDF

Info

Publication number
CA3066942A1
CA3066942A1 CA3066942A CA3066942A CA3066942A1 CA 3066942 A1 CA3066942 A1 CA 3066942A1 CA 3066942 A CA3066942 A CA 3066942A CA 3066942 A CA3066942 A CA 3066942A CA 3066942 A1 CA3066942 A1 CA 3066942A1
Authority
CA
Canada
Prior art keywords
formula
diazabicyclo
group
fluorine
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3066942A
Other languages
English (en)
French (fr)
Inventor
Martina Delbeck
Michael Hahn
Thomas Muller
Klemens Lustig
Karl COLLINS
Niels Lindner
Janine NICOLAI
Moritz Beck-Broichsitter
Udo Albus
Doris Gehring
Bjorn Rosenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Pharma AG
Original Assignee
Bayer AG
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Pharma AG filed Critical Bayer AG
Publication of CA3066942A1 publication Critical patent/CA3066942A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3066942A 2017-06-14 2018-06-07 Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders Pending CA3066942A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17176046 2017-06-14
EP17176046.5 2017-06-14
EP17193252.8 2017-09-26
EP17193252 2017-09-26
PCT/EP2018/064977 WO2018228907A1 (de) 2017-06-14 2018-06-07 Diazabicyclisch substituierte imidazopyrimidine und ihre verwendung zur behandlung von atemstörungen

Publications (1)

Publication Number Publication Date
CA3066942A1 true CA3066942A1 (en) 2018-12-20

Family

ID=62492660

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3066942A Pending CA3066942A1 (en) 2017-06-14 2018-06-07 Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders

Country Status (36)

Country Link
US (3) US11098063B2 (https=)
EP (1) EP3638675B1 (https=)
JP (2) JP6896113B2 (https=)
KR (1) KR102364134B1 (https=)
CN (4) CN115554300B (https=)
AR (1) AR112099A1 (https=)
AU (1) AU2018283331B2 (https=)
BR (1) BR112019026450A2 (https=)
CA (1) CA3066942A1 (https=)
CL (1) CL2019003650A1 (https=)
CO (1) CO2019014047A2 (https=)
CR (1) CR20190563A (https=)
CU (1) CU24603B1 (https=)
DO (1) DOP2019000308A (https=)
EA (1) EA202090043A1 (https=)
EC (1) ECSP19088492A (https=)
ES (1) ES2985167T3 (https=)
GE (2) GEAP202115256A (https=)
HR (1) HRP20240678T1 (https=)
HU (1) HUE066512T2 (https=)
IL (1) IL271117B (https=)
JO (1) JOP20190284A1 (https=)
MA (1) MA49368B1 (https=)
MX (2) MX2019014983A (https=)
MY (1) MY204293A (https=)
NI (1) NI201900126A (https=)
NZ (1) NZ758821A (https=)
PE (1) PE20200016A1 (https=)
PH (1) PH12019502828A1 (https=)
PL (1) PL3638675T3 (https=)
RS (1) RS65543B1 (https=)
SG (1) SG11201911508XA (https=)
TW (1) TWI801388B (https=)
UA (1) UA125186C2 (https=)
UY (1) UY37773A (https=)
WO (1) WO2018228907A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220218700A1 (en) * 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017097792A1 (de) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridin-derivate als blocker der task-1 und task-2 kanäle zur behandlung von schlafbedingten atemstörungen
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
US20220218695A1 (en) 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
CA3160035A1 (en) 2019-11-06 2021-05-14 Bayer Aktiengesellschaft Inhibitors of adrenoreceptor adrac2
BR112022026398A2 (pt) 2020-07-06 2023-01-17 Bayer Ag Combinação de antagonista de receptor ¿2 adrenérgico subtipo c (alfa-2c) com bloqueador de canal task1/3 para tratamento da apneia do sono
GB202101734D0 (en) * 2021-02-08 2021-03-24 Cerevance Inc Novel Compounds
US20250057845A1 (en) 2021-12-22 2025-02-20 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a p2x3 receptor antagonist for the treatment of sleep apnea
MX2024007764A (es) 2021-12-22 2024-07-04 Bayer Ag Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o.
KR20240124998A (ko) 2021-12-22 2024-08-19 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 task1/3 채널 차단제와 무스카린성 수용체 길항제의 조합물
CN118785902A (zh) 2022-01-07 2024-10-15 拜耳公司 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C拮抗剂
KR20240132345A (ko) 2022-01-07 2024-09-03 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 2,3-디히드로벤조[b][1,4]디옥신-2-일메틸)피페라진-1-일 유도체
AR133983A1 (es) 2023-09-28 2025-11-19 Bayer Ag Carboxamidas heterocíclicas sustituidas y su uso
CN117959293B (zh) * 2024-01-18 2025-05-13 香港大学深圳医院 非奈利酮在制备治疗和/或预防卵巢功能障碍疾病药物中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
AU2001270297A1 (en) 2000-06-30 2002-01-14 Neurogen Corporation 2-phenylimidazo(1,2-a)pyridine derivatives: a new class of gaba brain receptor ligands
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
RU2436577C2 (ru) 2006-04-27 2011-12-20 Санофи-Авентис Дойчланд Гмбх Ингибиторы ионных task-1 и task-3 каналов
CA2657623A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
CA2724842A1 (en) 2008-05-19 2009-11-26 Sunovion Pharmaceuticals Inc. Imidazo[1,2-a]pyridine compounds
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
SG184073A1 (en) 2010-03-18 2012-10-30 Pasteur Institut Korea Anti-infective compounds
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US9000186B2 (en) 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
CA2831356A1 (en) 2011-03-31 2012-10-04 Emblem Technology Transfer Gmbh Imidazo [1,2-a]pyridine_compounds for use in therapy
KR20140093610A (ko) 2011-04-21 2014-07-28 재단법인 한국파스퇴르연구소 소염 화합물
MX2014002968A (es) 2011-09-12 2014-07-09 Sanofi Sa 4,5,6,7 - tetrahidro - 1h - pirazolo [4,3 -c] piridinas sustituidas con indanilo, su uso como medicamento, y preparaciones farmaceuticas que las comprenden.
MX2014003181A (es) * 2011-09-16 2015-08-05 Sanofi Sa 4,5,6,7-tetrahidro-1h-pirazolo [4,3-c] piridinas sustituidas, su uso como medicamento y preparaciones farmacéuticas que las comprenden.
AU2011376721B2 (en) 2011-09-16 2017-06-08 Sanofi Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
UY34610A (es) 2012-02-03 2013-09-30 Sanofi Sa Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
EP3004088A1 (en) * 2013-05-24 2016-04-13 Iomet Pharma Ltd. Slc2a transporter inhibitors
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
TWI585785B (zh) 2014-11-26 2017-06-01 Murata Manufacturing Co Electronic parts manufacturing methods, electronic components and electronic devices
JP2018012645A (ja) 2014-11-26 2018-01-25 持田製薬株式会社 新規ジアザビシクロ誘導体
WO2016085784A1 (en) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Methyl diazepane orexin receptor antagonists
US9994570B2 (en) * 2014-11-26 2018-06-12 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
JP2018016544A (ja) 2014-12-03 2018-02-01 持田製薬株式会社 新規ジアザビシクロ［２．２．２］オクタン誘導体
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
WO2017097792A1 (de) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridin-derivate als blocker der task-1 und task-2 kanäle zur behandlung von schlafbedingten atemstörungen
US10414765B2 (en) 2015-12-10 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
PE20211285A1 (es) 2018-11-27 2021-07-19 Bayer Ag Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios
US20220218695A1 (en) 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
TW202108139A (zh) 2019-05-09 2021-03-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２—腎上腺素受體亞型Ｃ（α—２Ｃ）拮抗劑與ＴＡＳＫ１／３通道阻斷劑之組合

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220218700A1 (en) * 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea

Also Published As

Publication number Publication date
CL2019003650A1 (es) 2020-07-10
US20220017540A1 (en) 2022-01-20
US12180227B2 (en) 2024-12-31
AU2018283331B2 (en) 2022-08-04
UY37773A (es) 2019-01-02
MA49368B1 (fr) 2024-06-28
CN115554299A (zh) 2023-01-03
GEAP202115256A (en) 2021-10-11
PE20200016A1 (es) 2020-01-06
US20250154175A1 (en) 2025-05-15
PL3638675T3 (pl) 2024-07-01
CU20190101A7 (es) 2020-10-20
ECSP19088492A (es) 2019-12-27
MY204293A (en) 2024-08-21
CN115583959B (zh) 2024-04-26
CN110719911B (zh) 2022-10-21
CN115554300B (zh) 2024-10-29
CN110719911A (zh) 2020-01-21
MX2022012716A (es) 2022-11-07
KR20200014915A (ko) 2020-02-11
HUE066512T2 (hu) 2024-08-28
JP2021127346A (ja) 2021-09-02
JOP20190284A1 (ar) 2019-12-11
CO2019014047A2 (es) 2020-01-17
BR112019026450A2 (pt) 2020-07-14
IL271117B (en) 2022-03-01
MA49368A (fr) 2021-04-14
NI201900126A (es) 2020-04-02
HRP20240678T1 (hr) 2024-08-16
MX2019014983A (es) 2020-02-24
JP6896113B2 (ja) 2021-06-30
US11098063B2 (en) 2021-08-24
SG11201911508XA (en) 2020-01-30
CR20190563A (es) 2020-04-22
PH12019502828A1 (en) 2020-10-26
CU24603B1 (es) 2022-06-06
AR112099A1 (es) 2019-09-18
NZ758821A (en) 2025-05-02
TWI801388B (zh) 2023-05-11
IL271117A (en) 2020-01-30
JP2020523388A (ja) 2020-08-06
EP3638675A1 (de) 2020-04-22
US20200109155A1 (en) 2020-04-09
CN115554300A (zh) 2023-01-03
WO2018228907A1 (de) 2018-12-20
CN115583959A (zh) 2023-01-10
EP3638675C0 (de) 2024-04-17
ES2985167T3 (es) 2024-11-04
DOP2019000308A (es) 2020-01-31
AU2018283331A1 (en) 2019-12-19
UA125186C2 (uk) 2022-01-26
TW201919638A (zh) 2019-06-01
EA202090043A1 (ru) 2020-04-02
GEP20227366B (en) 2022-03-25
KR102364134B1 (ko) 2022-02-18
RS65543B1 (sr) 2024-06-28
EP3638675B1 (de) 2024-04-17

Similar Documents

Publication Publication Date Title
US12180227B2 (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
US10414765B2 (en) Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same
CA3007724C (en) 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
AU2017298421B2 (en) Substituted diazahetero-bicyclic compounds and their use
EP3638676B1 (en) Substituted bridged diazepane derivatives and use thereof as task-1 and task-3 inhibitors
HK40085266A (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
HK40085269A (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
HK40085266B (zh) 二氮杂双环取代的咪唑并嘧啶及其用於治疗呼吸障碍的用途
EA040559B1 (ru) Диазабициклические замещенные имидазопиримидины и их применение

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230605

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240807

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250606

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250606

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251124

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260126